Haloperidol as an anti-emetic for Cannabis Hyperemesis Syndrome in the ED
- PMID: 33835429
- DOI: 10.1007/s43678-021-00122-x
Haloperidol as an anti-emetic for Cannabis Hyperemesis Syndrome in the ED
Comment on
-
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.Ann Emerg Med. 2021 Jun;77(6):613-619. doi: 10.1016/j.annemergmed.2020.08.021. Epub 2020 Nov 5. Ann Emerg Med. 2021. PMID: 33160719 Clinical Trial.
References
-
- Jones J, Abernathy K. Successful treatment of suspected cannabinoid hyperemesis syndrome using haloperidol in the outpatient setting. Case Rep Psychiatry. 2016. https://doi.org/10.1155/2016/3614053] . - DOI - PubMed - PMC
-
- Hickey JC, Witsil JC, Mycyk M. Haloperidol for treatment of cannabinoid hyperemesis syndrome. Am J Emerg Med. 2013;31(6):1003.e3-1003.e6. https://doi.org/10.1016/j.ajem.2013.02.021] . - DOI
-
- Yazbeck-Karam VG, Siddik-Sayyid SM, Barakat HB, et al. Haloperidol versus ondansetron for treatment of established nausea and vomiting following general anesthesia: a randomized clinical trial. AnesthAnalg. 2017;124(2):438–44.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources